InvestorsHub Logo
Followers 18
Posts 643
Boards Moderated 0
Alias Born 05/19/2017

Re: Paulness post# 1396

Friday, 03/10/2023 5:52:19 PM

Friday, March 10, 2023 5:52:19 PM

Post# of 1456
More durable and reliable progress. Good stuff. ARVO a month from now! 23-27 April.

https://www.arvo.org/annual-meeting/

https://www.businesswire.com/news/home/20230306005224/en/RG6501-OpRegen®-Phase-12a-Results-to-Be-Featured-at-2023-Association-for-Research-in-Vision-and-Ophthalmology-ARVO-Annual-Meeting-in-Presentation-by-Eyal-Banin-M.D.-Ph.D.

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes in addition to visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The meeting will be held April 23 – 27, 2023 at the Ernest N. Morial Convention Center in New Orleans, LA. The presentation, “Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial” will be featured as part of the Paper Session, on April 25, 2023 between 12:30 PM to 12:45 PM MDT, by Eyal Banin, M.D., Ph.D., Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology at Hadassah-Hebrew University Medical Center (presentation number 2826, session number 331). RG6501 (OpRegen) is a retinal pigment epithelium cell transplant therapy currently in development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). It is being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech, a member of the Roche Group, and is currently being evaluated in a Phase 2a clinical study in patients with geographic atrophy secondary to age-related macular degeneration (ClinicalTrials.gov Identifier: NCT05626114).

https://hadassah-hospital.org/doctor/eyal-banin.htm
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LCTX News